8-K
filed June 18, 2026, 4:30 PM ET
ticker PTGX
CIK 0001377121
other material
confidence high
sentiment neutral
materiality 0.40
Protagonist Therapeutics stockholders approve 2026 equity plan, adding 650K new shares
Protagonist Therapeutics, Inc
- Stockholders approved adoption of 2026 Equity Incentive Plan, replacing 2016 plan; adds 650,000 new shares plus carryover from prior plan and returning shares.
- Dinesh Patel and Lewis Williams re-elected as Class I directors with 48.7M and 45.4M votes for, respectively.
- Say-on-pay passed: 53.4M for, 3.2M against; Ernst & Young ratified as independent auditor (59.4M for, 28K against).
- Plan approval received 47.7M for, 8.8M against; broker non-votes of 2.8M on all proposals except auditor ratification.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Protagonist Therapeutics, Inc shareholders approved Approval, on a non-binding advisory basis, of the compensation of the named executive officers.
- Proposal
- say on pay
- Outcome
- passed
Exact text from the filing
Proposal 2 — To approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers. This proposal was approved by the requisite vote, with the votes thereon as follows: Final Voting Results For Against Abstentions Broker Non-Votes 53,412,559 3,164,702 12,752 2,819,234
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Protagonist Therapeutics, Inc shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-12-31 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-12-31
Exact text from the filing
Proposal 3 — To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2026. This proposal was approved by the requisite vote, with the votes thereon as follows: Final Voting Results For Against Abstentions Broker Non-Votes 59,371,487 28,221 9,539 —
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Protagonist Therapeutics, Inc shareholders approved Election of two Class I director nominees.
- Proposal
- director election
- Outcome
- passed
Exact text from the filing
Proposal 1 — To elect the two Class I director nominees to hold office until the 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified. Each of the two nominees was so elected, with the votes thereon as follows: Final Voting Results Nominee For Withheld Broker Non-Votes Dinesh V. Patel, Ph.D. 48,714,702 7,875,311 2,819,234 Lewis T. “Rusty” Williams, M.D., Ph.D. 45,371,193 11,218,820 2,819,234
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Protagonist Therapeutics, Inc shareholders approved Approval of the adoption of the Company’s 2026 Equity Incentive Plan.
- Proposal
- equity plan
- Outcome
- passed
Exact text from the filing
Proposal 4 — To approve the adoption of the Company’s 2026 Equity Incentive Plan. This proposal was approved by the requisite vote, with the votes thereon as follows: Final Voting Results For Against Abstentions Broker Non-Votes 47,745,562 8,826,703 17,748 2,819,234
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.